Aquestive Therapeutics, Inc. – NASDAQ:AQST
Aquestive Therapeutics stock price today
$3.88
+0.35
+10.23%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Aquestive Therapeutics stock price monthly change
+31.84%
month
Aquestive Therapeutics stock price quarterly change
+31.84%
quarter
Aquestive Therapeutics stock price yearly change
+75.12%
year
Aquestive Therapeutics key metrics
Market Cap | 322.31M |
Enterprise value | 32.16M |
P/E | -0.9 |
EV/Sales | 0.43 |
EV/EBITDA | -0.52 |
Price/Sales | 0.73 |
Price/Book | -0.45 |
PEG ratio | -0.01 |
EPS | -0.42 |
Revenue | 51.50M |
EBITDA | -18.36M |
Income | -28.76M |
Revenue Q/Q | 8.25% |
Revenue Y/Y | 10.65% |
Profit margin | -114.64% |
Oper. margin | -88.19% |
Gross margin | 31.3% |
EBIT margin | -88.19% |
EBITDA margin | -35.65% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAquestive Therapeutics stock price history
Aquestive Therapeutics stock forecast
Aquestive Therapeutics financial statements
Average Price Target
$10
Potential upside: 157.73%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 13.24M | -5.79M | -43.74% |
|---|---|---|---|
| Sep 2023 | 13.00M | -2.03M | -15.65% |
| Dec 2023 | 13.20M | -8.11M | -61.42% |
| Mar 2024 | 12.05M | -12.82M | -106.43% |
| Jun 2023 | 56994000 | 163.64M | 287.13% |
|---|---|---|---|
| Sep 2023 | 59448000 | 162.37M | 273.14% |
| Dec 2023 | 57418000 | 163.90M | 285.46% |
| Mar 2024 | 129523000 | 165.82M | 128.03% |
| Jun 2023 | -7.90M | -826K | 4.28M |
|---|---|---|---|
| Sep 2023 | -2.34M | -151K | 4.97M |
| Dec 2023 | -4.94M | -16K | 3.91M |
| Mar 2024 | -10.38M | -29K | 81.74M |
Aquestive Therapeutics alternative data
| Aug 2023 | 130 |
|---|---|
| Sep 2023 | 130 |
| Oct 2023 | 130 |
| Nov 2023 | 130 |
| Dec 2023 | 130 |
| Jan 2024 | 130 |
| Feb 2024 | 130 |
| Mar 2024 | 135 |
| Apr 2024 | 135 |
| May 2024 | 135 |
| Jun 2024 | 135 |
| Jul 2024 | 135 |
Aquestive Therapeutics other data
33.16%
-7.18%
of AQST is owned by hedge funds
15.07M
-1.65M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 75000 |
| Nov 2024 | 0 | 44 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | JUNG CASSIE officer: Chief Operating Officer | Common Stock | 44 | $4.87 | $214 | ||
Sale | SCHOBEL ALEXANDER MARK officer: Chief Innovation/Tech .. | Common Stock | 50,000 | $6 | $300,000 | ||
Sale | SCHOBEL ALEXANDER MARK officer: Chief Innovation/Tech .. | Common Stock | 25,000 | $5.19 | $129,675 | ||
Purchase | BOYD PETER E. officer: SVP-Bus. Process & Inf.. | Common Stock | 5,000 | $0.81 | $4,050 | ||
Purchase | BRAENDER LORI J officer: General Counsel | Warrant (Right to Buy) | 13,761 | $0.96 | $13,211 | ||
Purchase | BRAENDER LORI J officer: General Counsel | Common Stock | 13,761 | $0.96 | $13,211 | ||
Purchase | SCHOBEL ALEXANDER MARK officer: Chief Innovation/Tech .. | Common Stock | 45,871 | $0.96 | $44,036 | ||
Purchase | BARBER DANIEL officer: Chief Ex.. | Warrant (Right to Buy) | 91,743 | $0.96 | $88,073 | ||
Purchase | BARBER DANIEL officer: Chief Ex.. | Common Stock | 91,743 | $0.96 | $88,073 | ||
Purchase | BOYD PETER E. officer: SVP-Bus. Process & Inf.. | Warrant (Right to Buy) | 2,293 | $0.96 | $2,201 |
| Patent |
|---|
Application Filling date: 15 Jan 2022 Issue date: 28 Jul 2022 |
Application Filling date: 13 Dec 2021 Issue date: 26 May 2022 |
Application Filling date: 29 Sep 2021 Issue date: 24 Mar 2022 |
Application Filling date: 31 Aug 2021 Issue date: 24 Feb 2022 |
Grant Filling date: 3 Aug 2020 Issue date: 28 Dec 2021 |
Grant Filling date: 4 May 2017 Issue date: 7 Dec 2021 |
Grant Filling date: 4 May 2017 Issue date: 2 Nov 2021 |
Application Filling date: 24 Sep 2020 Issue date: 12 Aug 2021 |
Grant Filling date: 17 Dec 2019 Issue date: 3 Aug 2021 |
Application Filling date: 14 Nov 2020 Issue date: 20 May 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 6 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share
Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside
Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential
Aquestive Therapeutics: Five Foci For 2025
Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1
ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both
Aquestive Therapeutics: Developing A Better Solution To A $1 Billion/Year Anaphylaxis Problem
Assertio Holdings: Acquiring Good Products Is The Key To Success
-
What's the price of Aquestive Therapeutics stock today?
One share of Aquestive Therapeutics stock can currently be purchased for approximately $3.88.
-
When is Aquestive Therapeutics's next earnings date?
Unfortunately, Aquestive Therapeutics's (AQST) next earnings date is currently unknown.
-
Does Aquestive Therapeutics pay dividends?
No, Aquestive Therapeutics does not pay dividends.
-
How much money does Aquestive Therapeutics make?
Aquestive Therapeutics has a market capitalization of 322.31M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 6.09% to 50.58M US dollars.
-
What is Aquestive Therapeutics's stock symbol?
Aquestive Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "AQST".
-
What is Aquestive Therapeutics's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Aquestive Therapeutics?
Shares of Aquestive Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Aquestive Therapeutics's key executives?
Aquestive Therapeutics's management team includes the following people:
- Mr. Keith J. Kendall Chief Executive Officer, Pres & Director(age: 67, pay: $1,030,000)
- Mr. Daniel Barber Senior Vice President & Chief Operating Officer(age: 49, pay: $713,280)
-
How many employees does Aquestive Therapeutics have?
As Jul 2024, Aquestive Therapeutics employs 135 workers.
-
When Aquestive Therapeutics went public?
Aquestive Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 25 Jul 2018.
-
What is Aquestive Therapeutics's official website?
The official website for Aquestive Therapeutics is aquestive.com.
-
Where are Aquestive Therapeutics's headquarters?
Aquestive Therapeutics is headquartered at 30 Technology Drive, Warren, NJ.
-
How can i contact Aquestive Therapeutics?
Aquestive Therapeutics's mailing address is 30 Technology Drive, Warren, NJ and company can be reached via phone at +90 89411900.
-
What is Aquestive Therapeutics stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Aquestive Therapeutics in the last 12 months, the avarage price target is $10. The average price target represents a 157.73% change from the last price of $3.88.
Aquestive Therapeutics company profile:
Aquestive Therapeutics, Inc.
aquestive.comExchange:
NASDAQ
Full time employees:
135
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
30 Technology Drive
Warren, NJ 07059
Warren, NJ 07059
CIK: 0001398733
ISIN: US03843E1047
CUSIP: 03843E104
